What We're Reading: Page 177
Industry reads hand-picked by our editors
Nov 05, 2020
-
The Wall Street Journal
After Rocky Start, FDA’s Hahn Wins Over Skeptics
-
Reuters
WHO-led COVID drug scheme doubles down on antibodies, steroids and shuns remdesivir
-
BioCentury
HHS proposes regulation sunset rule that could create uncertainty for industry, paralyze FDA
-
Bloomberg
China Alzheimer Drug Seeks Global Legitimacy With U.S. Trial
Nov 04, 2020
Nov 03, 2020
-
Reuters
FDA bars critic from review panel of Biogen's controversial Alzheimer's drug
-
STAT
Is Philadelphia’s biotech cluster faltering? Experts say no, even as funding dwindles
-
POLITICO
Health agencies resist Trump civil service executive order
-
FiercePharma
Orchard Therapeutics' gene therapy Strimvelis linked to a leukemia case
Nov 02, 2020
Oct 30, 2020
-
Associated Press
Lab tests show risks of using CRISPR gene editing on embryos
-
Axios
States beg for Warp Speed billions to distribute COVID-19 vaccines
-
AstraZeneca
AstraZeneca sells commercial rights to two drugs in $400 million deal
-
Bloomberg
How Hims Built An Online Prescription Drug Empire On Outdated Oversight
Oct 29, 2020
-
Science
The ‘very, very bad look’ of remdesivir, the first FDA-approved COVID-19 drug
-
Reuters
U.S. drugmakers, bracing for price cuts, shift election support toward Democrats
-
FierceBiotech
Gilead stops 3 filgotinib trials pending FDA feedback on faltering JAK1 inhibitor
-
Bloomberg
Moderna Received $1.1 Billion in Deposits for Covid Vaccines in Quarter
Oct 28, 2020
-
The New York Times
In a Battered New York Office Market, Life Science Is Flourishing
-
STAT
Can boosting the 'bliss molecule' help treat mental health conditions? An oft-failed idea gets another shot
-
USA Today
FDA COVID vaccine chief: We'll be independent, transparent, trustworthy
-
Financial Times
GSK reassures on profits as standard vaccination levels recover
Previous
